Toronto Dominion Bank
CNCR

Toronto Dominion Bank’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Toronto Dominion Bank’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,716
Closed -$21K – 1480
2019
Q2 		$21K Buy
+1,716
New +$35.3K ﹤0.01% 1253
2018
Q3 		– Sell
-858
Closed -$21K – 1414
2018
Q2 		$21K Buy
+858
New +$23.1K ﹤0.01% 1266

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank's CNCR Position: Q3 2019 in Review

Toronto Dominion Bank sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2019, closing a stake of 1,716 shares — an estimated $21K sold.

Toronto Dominion Bank first reported a position in CNCR in Q2 2018 and held it in 2 quarters. The position peaked at $21K in Q2 2019. 22 funds tracked by Wall St. Rank hold CNCR as of Q3 2019.

  • Toronto Dominion Bank reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2019 after selling out during the quarter.
  • Toronto Dominion Bank sold 1,716 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2019, an estimated $21K.
  • Toronto Dominion Bank first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2018 and held it in 2 quarters.
  • Toronto Dominion Bank's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $21K in Q2 2019.
  • 22 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2019.

Based on Toronto Dominion Bank's 13F filing for Q3 2019, filed 12 Nov 2019.